Fluicell AB (OSTO:FLUI) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:FLUI Fluicell AB OSTO:FLUI
58 GF Score
Price kr34.60
GF Value kr33.43
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

OSTO:FLUI
58GF Score
Fluicell AB OSTO:FLUI
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be overvalued. The current stock price of kr34.60 is trading 3.5% above its estimated GF Value™ of kr33.43. GuruFocus considers Fluicell AB to be Fairly Valued.

Key valuation signals for OSTO:FLUI:

  • Total Premiums Earned:
  • GF Value™: kr33.43 vs. price of kr34.60 (3.5% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
58GF Score

Get the complete analysis for OSTO:FLUI

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.60
Price
kr33.43
GF Value